Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/166002
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20 ) and 557 days for IE (283,187.45 ). Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
HIDALGO-TENORIO, Carmen, VINUESA, David, PLATA, Antonio, MARTÍN-DÁVILA, Pilar, IFTIMIE, Simona, SEQUERA, Sergio, LOECHES, Belén, LÓPEZ CORTÉS, Luis eduardo, FARIÑAS, Mari carmen, FERNÁNDEZ-ROLDAN, Concepción, JAVIER-MARTINEZ, Rosario, MUÑOZ, Patricia, ARENAS-MIRAS, Maria del mar, MARTÍNEZ-MARCOS, Francisco javier, MIRÓ MEDA, José m. (josé maría), HERRERO, Carmen, BERECIARTUA, Elena, DE, Jesus, PASQUAU, Juan. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. _Annals of Clinical Microbiology and Antimicrobials_. 2019. Vol. 18, núm. 30. [consulta: 24 de gener de 2026]. ISSN: 1476-0711. [Disponible a: https://hdl.handle.net/2445/166002]